Literature DB >> 28721448

[PI-RADS 2.0 for Prostate MRI].

T Franiel1, M Röthke2.   

Abstract

The PI-RADS 2.0 classification was established by an international collaboration of the European Society of Urogenital Radiology (ESUR), the American College of Radiology (ACR), and AdMetech Foundation to globally standardize the acquisition and interpretation of multiparametric prostate magnetic resonance imaging (MRI). The PI-RADS 2.0 aims to improve the detection, localization, staging and risk stratification of patients with suspected or histologically confirmed prostate cancer. Suspicious areas on T2-weighted (T2w) MRI, diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) were assessed for the presence of a clinically significant prostate cancer with scale from 1 to 5 with 5 being most likely to represent clinically significant prostate cancer. The dominant sequence to detect significant prostate cancer in the peripheral zone is DWI and for the transition zone T2w images. For the local staging of prostate cancer criteria for the assessment of an extracapsular growth were formulated.

Entities:  

Keywords:  Localisation; Magnetic resonance imaging; Prostatic neoplasms; Risk stratification; Staging

Mesh:

Substances:

Year:  2017        PMID: 28721448     DOI: 10.1007/s00117-017-0269-0

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  20 in total

1.  Seminal vesicle invasion: accuracy and analysis of infiltration patterns with high-spatial resolution T2-weighted sequences on endorectal magnetic resonance imaging.

Authors:  M Roethke; S Kaufmann; M Kniess; D Ketelsen; C D Claussen; H P Schlemmer; A Stenzl; D Schilling
Journal:  Urol Int       Date:  2013-11-26       Impact factor: 2.089

Review 2.  MRI of the Prostate: Recommendations on Patient Preparation and Scanning Protocol.

Authors:  Tobias Franiel; Michael Quentin; Ullrich Gerd Mueller-Lisse; Lars Schimmoeller; Patrick Asbach; Stefan Rödel; Winfried Willinek; Katja Hueper; Dirk Beyersdorff; Matthias Röthke
Journal:  Rofo       Date:  2016-12-21

3.  Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.

Authors:  Andrew B Rosenkrantz; James S Babb; Samir S Taneja; Justin M Ream
Journal:  Radiology       Date:  2016-10-26       Impact factor: 11.105

4.  Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.

Authors:  Panu P Tonttila; Juha Lantto; Eija Pääkkö; Ulla Piippo; Saila Kauppila; Eveliina Lammentausta; Pasi Ohtonen; Markku H Vaarala
Journal:  Eur Urol       Date:  2015-05-29       Impact factor: 20.096

5.  Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.

Authors:  Michael Quentin; Dirk Blondin; Christian Arsov; Lars Schimmöller; Andreas Hiester; Erhard Godehardt; Peter Albers; Gerald Antoch; Robert Rabenalt
Journal:  J Urol       Date:  2014-05-24       Impact factor: 7.450

6.  Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.

Authors:  Christian Arsov; Robert Rabenalt; Dirk Blondin; Michael Quentin; Andreas Hiester; Erhard Godehardt; Helmut E Gabbert; Nikolaus Becker; Gerald Antoch; Peter Albers; Lars Schimmöller
Journal:  Eur Urol       Date:  2015-06-23       Impact factor: 20.096

7.  Assessment of PI-RADS v2 for the Detection of Prostate Cancer.

Authors:  Moritz Kasel-Seibert; Thomas Lehmann; René Aschenbach; Felix V Guettler; Mohamed Abubrig; Marc-Oliver Grimm; Ulf Teichgraeber; Tobias Franiel
Journal:  Eur J Radiol       Date:  2016-01-19       Impact factor: 3.528

8.  Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging.

Authors:  Harriet C Thoeny; Johannes M Froehlich; Maria Triantafyllou; Juerg Huesler; Lauren J Bains; Peter Vermathen; Achim Fleischmann; Urs E Studer
Journal:  Radiology       Date:  2014-06-02       Impact factor: 11.105

9.  Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion.

Authors:  Eli Gibson; Glenn S Bauman; Cesare Romagnoli; Derek W Cool; Matthew Bastian-Jordan; Zahra Kassam; Mena Gaed; Madeleine Moussa; José A Gómez; Stephen E Pautler; Joseph L Chin; Cathie Crukley; Masoom A Haider; Aaron Fenster; Aaron D Ward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-21       Impact factor: 7.038

10.  Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol.

Authors:  Oscar A Debats; Ansje S Fortuin; Hanneke J M Meijer; Thomas Hambrock; Geert J S Litjens; Jelle O Barentsz; Henkjan J Huisman
Journal:  PeerJ       Date:  2016-10-20       Impact factor: 2.984

View more
  2 in total

Review 1.  [Predictive biomarkers in oncologic uropathology].

Authors:  H Reis; T Szarvas; V Grünwald
Journal:  Pathologe       Date:  2019-05       Impact factor: 1.011

Review 2.  [PI-RADS 2.1 and structured reporting of magnetic resonance imaging of the prostate].

Authors:  Andreas Hötker; Olivio F Donati
Journal:  Radiologe       Date:  2021-07-02       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.